Center for Scientific Review; Notice of Closed Meetings., 35965-35966 [2015-15308]
Download as PDF
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 120 / Tuesday, June 23, 2015 / Notices
continuing applications and foreign
counterparts to Absino Co., Ltd, a
company having a place of business in
Beijing, China.
The patent rights in these inventions
have (a) been assigned to the United
States of America, as represented by the
Secretary, Department of Health and
Human Services who has delegated
authority for the licensing of inventions
to the National Institutes of Health or (b)
been exclusively licensed to the
National Institutes of Health.
The prospective start-up exclusive
evaluation option license territory may
be China, the U.S., and Europe, and the
field of use may be limited to the
development of bispecific multivalent
human immunodeficiency virus type 1
(HIV–1) neutralizing fusion proteins as
HIV entry inhibitors for the treatment of
HIV infections.
Upon the expiration or termination of
the start-up exclusive evaluation option
license, Absino Co., Ltd will have the
exclusive right to execute an exclusive
commercialization license which will
supersede and replace the start-up
exclusive evaluation option license with
no greater field of use and territory than
granted in the start-up exclusive
evaluation option license.
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before July 8,
2015 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated start-up exclusive
evaluation option license should be
directed to: Sally Hu, Ph.D., M.B.A.,
Senior Licensing and Patenting
Manager, Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 435–5606; Facsimile: (301) 402–
0220; Email: hus@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
subject technology is HIV–1 entry
inhibitors that can neutralize many
subtypes of HIV–1 isolates including
clade A–E and tropism R5 and X4 (using
either CCR5 or CXCR4 co-receptor for
entry). These entry inhibitors are fusion
proteins and have a potency about 10fold higher than that of the broadly
neutralizing antibody VRC01 that is in
Phase I clinical trial, or 50-fold higher
than that of the FDA approved HIV
entry inhibitor Fuzeon. Therefore, these
fusion proteins are promising drug
candidates for HIV/AIDS prevention
and treatment.
The prospective start-up exclusive
evaluation option license will be royalty
VerDate Sep<11>2014
18:39 Jun 22, 2015
Jkt 235001
bearing and will comply with the terms
and conditions of 35 U.S.C. 209 and 37
CFR part 404. The prospective start-up
exclusive evaluation option license may
be granted unless within fifteen (15)
days from the date of this published
notice, the NIH receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated start-up exclusive
evaluation option license. Comments
and objections submitted to this notice
will not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: June 16, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology
Transfer, National Institutes of Health.
[FR Doc. 2015–15334 Filed 6–22–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Library of
Medicine Special Emphasis Panel; Conflicts
R01/R21/R13.
Date: July 30, 2015.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Library of Medicine, 6705
Rockledge Drive, Suite 301, Bethesda, MD
20817, (Telephone Conference Call).
Contact Person: Zoe E. Huang, MD.,
Scientific Review Officer, Extramural
Programs, National Library of Medicine, NIH,
6705 Rockledge Drive, Suite 301, Bethesda,
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
35965
MD 20892–7968, 301–594–4937, huangz@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
Assistance, National Institutes of Health,
HHS)
Dated: June 17, 2015.
Michelle Trout,
Program Analyst, Office of the Federal
Advisory Committee Policy.
[FR Doc. 2015–15299 Filed 6–22–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings.
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Endocrinology, Metabolism,
Nutrition and Reproductive Sciences.
Date: July 14, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Dianne Hardy, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6175,
MSC 7892, Bethesda, MD 20892, 301–435–
1154, dianne.hardy@nih.gov.
Name of Committee: AIDS and Related
Research Integrated Review Group;
NeuroAIDS and other End-Organ Diseases
Study Section.
Date: July 23, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hyatt Regency Bethesda, One
Bethesda Metro Center, 7400 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: Eduardo A Montalvo,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
E:\FR\FM\23JNN1.SGM
23JNN1
mstockstill on DSK4VPTVN1PROD with NOTICES
35966
Federal Register / Vol. 80, No. 120 / Tuesday, June 23, 2015 / Notices
MSC 7852, Bethesda, MD 20892, (301) 435–
1168, montalve@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; PAR–13–
327: Innovative Molecular Analysis
Technology Development for Cancer
Research and Clinical Care.
Date: July 23, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Zhang-Zhi Hu, MD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6186,
MSC 7804, Bethesda, MD 20892, (301) 594–
2414, huzhuang@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Musculoskeletal Rehabilitation.
Date: July 23, 2015.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Rajiv Kumar, Ph.D., Chief,
MOSS IRG, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 4216, MSC 7802, Bethesda, MD
20892, 301–435–1212, kumarra@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; FOA:
RM15–002 Exploratory Technologies.
Date: July 24, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Embassy Row Hotel, 2015
Massachusetts Avenue NW., Washington, DC
20036.
Contact Person: Robert C. Elliott, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3130,
MSC 7850, Bethesda, MD 20892, 301–435–
3009, elliotro@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Clinical
Neuroscience and Neurodegeneration.
Date: July 24, 2015.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
Contact Person: Alessandra C Rovescalli,
Ph.D., Scientific Review Officer, National
Institutes of Health, Center for Scientific
Review, 6701 Rockledge Drive, Rm 5205
MSC7846, Bethesda, MD 20892, (301) 435–
1021, rovescaa@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Bacterial Pathogenesis
and Host Interactions.
Date: July 24, 2015.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
VerDate Sep<11>2014
18:39 Jun 22, 2015
Jkt 235001
Contact Person: Soheyla Saadi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3211,
MSC 7808, Bethesda, MD 20892, 301–435–
0903, saadisoh@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 17, 2015.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–15308 Filed 6–22–15; 8:45 am]
BILLING CODE 4140–01–P
Dated: June 17, 2015.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–15304 Filed 6–22–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Internal Agency Docket No. FEMA–4223–
DR; Docket ID FEMA–2015–0002]
Texas; Amendment No. 1 to Notice of
a Major Disaster Declaration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
National Institutes of Health
ACTION:
National Center For Complementary &
Integrative Health; Notice of Closed
Meeting
SUMMARY:
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Center for
Complementary and Integrative Health
Special Emphasis Panel; NCCIH Complex
Trials.
Date: July 13, 2015.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Democracy 2, Suite 401, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Hungyi Shau, Ph.D.,
Scientific Review Officer, National Center for
Complementary and Integrative Health,
National Institutes of Health, 6707
Democracy Boulevard, Suite 401, Bethesda,
MD 20892, 301–402–1030, Hungyi.Shau@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.213, Research and Training
in Complementary and Alternative Medicine,
National Institutes of Health, HHS)
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
Federal Emergency
Management Agency, DHS.
Notice.
This notice amends the notice
of a major disaster declaration for the
State of Texas (FEMA–4223–DR), dated
May 29, 2015, and related
determinations.
DATES:
Effective Date: June 5, 2015.
FOR FURTHER INFORMATION CONTACT:
Dean Webster, Office of Response and
Recovery, Federal Emergency
Management Agency, 500 C Street SW.,
Washington, DC 20472, (202) 646–2833.
The notice
of a major disaster declaration for the
State of Texas is hereby amended to
include the following areas among those
areas determined to have been adversely
affected by the event declared a major
disaster by the President in his
declaration of May 29, 2015.
SUPPLEMENTARY INFORMATION:
Bastrop, Blanco, Caldwell, Denton,
Eastland, Fort Bend, Guadalupe, Henderson,
Hidalgo, Johnson, Milam, Montague, Rusk,
Smith, Travis, Wichita, Williamson, and
Wise Counties for Individual Assistance.
Gaines and Navarro Counties for
Individual Assistance (already designated for
Public Assistance).
The following Catalog of Federal Domestic
Assistance Numbers (CFDA) are to be used
for reporting and drawing funds: 97.030,
Community Disaster Loans; 97.031, Cora
Brown Fund; 97.032, Crisis Counseling;
97.033, Disaster Legal Services; 97.034,
Disaster Unemployment Assistance (DUA);
97.046, Fire Management Assistance Grant;
97.048, Disaster Housing Assistance to
Individuals and Households In Presidentially
Declared Disaster Areas; 97.049,
Presidentially Declared Disaster Assistance—
Disaster Housing Operations for Individuals
and Households; 97.050 Presidentially
Declared Disaster Assistance to Individuals
and Households—Other Needs; 97.036,
Disaster Grants—Public Assistance
E:\FR\FM\23JNN1.SGM
23JNN1
Agencies
[Federal Register Volume 80, Number 120 (Tuesday, June 23, 2015)]
[Notices]
[Pages 35965-35966]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-15308]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings.
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Fellowships: Endocrinology, Metabolism, Nutrition and
Reproductive Sciences.
Date: July 14, 2015.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Dianne Hardy, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 6175, MSC 7892, Bethesda, MD 20892, 301-435-
1154, dianne.hardy@nih.gov.
Name of Committee: AIDS and Related Research Integrated Review
Group; NeuroAIDS and other End-Organ Diseases Study Section.
Date: July 23, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hyatt Regency Bethesda, One Bethesda Metro Center, 7400
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Eduardo A Montalvo, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5108,
[[Page 35966]]
MSC 7852, Bethesda, MD 20892, (301) 435-1168, montalve@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; PAR-13-327: Innovative Molecular Analysis Technology
Development for Cancer Research and Clinical Care.
Date: July 23, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Zhang-Zhi Hu, MD, Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 6186, MSC 7804, Bethesda, MD 20892, (301) 594-
2414, huzhuang@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Musculoskeletal Rehabilitation.
Date: July 23, 2015.
Time: 2:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference Call).
Contact Person: Rajiv Kumar, Ph.D., Chief, MOSS IRG, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge
Drive, Room 4216, MSC 7802, Bethesda, MD 20892, 301-435-1212,
kumarra@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; FOA: RM15-002 Exploratory Technologies.
Date: July 24, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: The Embassy Row Hotel, 2015 Massachusetts Avenue NW.,
Washington, DC 20036.
Contact Person: Robert C. Elliott, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3130, MSC 7850, Bethesda, MD
20892, 301-435-3009, elliotro@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Clinical Neuroscience and Neurodegeneration.
Date: July 24, 2015.
Time: 8:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892.
Contact Person: Alessandra C Rovescalli, Ph.D., Scientific
Review Officer, National Institutes of Health, Center for Scientific
Review, 6701 Rockledge Drive, Rm 5205 MSC7846, Bethesda, MD 20892,
(301) 435-1021, rovescaa@mail.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Topics in Bacterial Pathogenesis and Host
Interactions.
Date: July 24, 2015.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892.
Contact Person: Soheyla Saadi, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3211, MSC 7808, Bethesda, MD 20892, 301-435-
0903, saadisoh@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: June 17, 2015.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-15308 Filed 6-22-15; 8:45 am]
BILLING CODE 4140-01-P